Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities

BACKGROUND: The prognosis of patients with recurrent/refractory acute myelogenous leukemia (AML) remains poor and cell-based immunotherapies hold promise to improve outcomes. Natural Killer (NK) cells can elicit an antileukemic response via a repertoire of activating receptors that bind AML surface...

Descripción completa

Detalles Bibliográficos
Autores principales: Christodoulou, Ilias, Ho, Won Jin, Marple, Andrew, Ravich, Jonas W, Tam, Ada, Rahnama, Ruyan, Fearnow, Adam, Rietberg, Cambrynne, Yanik, Sean, Solomou, Elena E, Varadhan, Ravi, Koldobskiy, Michael A, Bonifant, Challice L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655609/
https://www.ncbi.nlm.nih.gov/pubmed/34896980
http://dx.doi.org/10.1136/jitc-2021-003894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655609/
https://www.ncbi.nlm.nih.gov/pubmed/34896980
http://dx.doi.org/10.1136/jitc-2021-003894

Ejemplares similares